Role of p53 circuitry in tumorigenesis: A brief review

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · see citing works

Modes of p53 regulation.

Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · see citing works

HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention

Yang, X.-J., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210599 · Cited by 1,040 · see citing works

Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization

Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. J. (2002) · Nature · doi:10.1038/nature737 · Cited by 1,027 · see citing works

p53 ubiquitination: Mdm2 and beyond

Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924 · see citing works

The emerging complexity of protein ubiquitination

Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821 · see citing works

p53 isoforms can regulate p53 transcriptional activity

Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810 · see citing works

Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation

Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 717 · see citing works

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · see citing works

The ubiquitin ligase COP1 is a critical negative regulator of p53

Dornan, D., Wertz, I. E., Shimizu, H., Arnott, D. P., Frantz, G. D., Dowd, P., Rourke, K. O., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 700 · see citing works

Structure-based design of potent non-peptide MDM2 inhibitors

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

Cell Cycle Regulation by Checkpoints

Barnum, K. J., & O’Connell, M. J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0888-2_2 · Cited by 609 · see citing works

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · see citing works

E2 enzymes: more than just middle men

Stewart, M. D., Ritterhoff, T., Klevit, R. E., & Brzović, P. S. (2016) · Cell Research · doi:10.1038/cr.2016.35 · Cited by 585 · see citing works

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

Laı́n, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A. R., Appleyard, V. C. L., Murray, K. E., Baker, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.004 · Cited by 523 · see citing works

MicroRNAs in the p53 network: micromanagement of tumour suppression

Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518 · see citing works

Types of Ubiquitin Ligases

Morreale, F. E., & Walden, H. (2016) · Cell · doi:10.1016/j.cell.2016.03.003 · Cited by 495 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Hyer, M. L., Milhollen, M. A., Ciavarri, J., Fleming, P., Traore, T., Sappal, D., Huck, J., Shi, J., Gavin, J., Brownell, J., et al. (2018) · Nature Medicine · doi:10.1038/nm.4474 · Cited by 447 · see citing works

The family of ubiquitin‐conjugating enzymes (E2s): deciding between life and death of proteins

van Wijk, S. J. L., & Timmers, H. T. M. (2009) · The FASEB Journal · doi:10.1096/fj.09-136259 · Cited by 434 · see citing works

Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells

Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433 · see citing works

Uncovering the role of p53 splice variants in human malignancy: a clinical perspective

Bourdon, J., Surget, S., & Khoury, M. P. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s53876 · Cited by 380 · see citing works

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354 · see citing works

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · see citing works

Targeting Oncogenic Mutant p53 for Cancer Therapy

Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 335 · see citing works

p53 Acetylation: Regulation and Consequences

Reed, S. M., & Quelle, D. E. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 330 · see citing works

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328 · see citing works

SIRT1, Is It a Tumor Promoter or Tumor Suppressor?

Deng, C. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.147 · Cited by 323 · see citing works

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290 · see citing works

The multiple levels of regulation by p53 ubiquitination

Lee, J. T., & Gu, W. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.77 · Cited by 289 · see citing works

The impact of acetylation and deacetylation on the p53 pathway

Brooks, C. L., & Gu, W. J. (2011) · Protein & Cell · doi:10.1007/s13238-011-1063-9 · Cited by 279 · see citing works

Cytoplasmic destruction of p53 by the endoplasmic reticulum‐resident ubiquitin ligase ‘Synoviolin’

Yamasaki, S., Yagishita, N., Sasaki, T., Nakazawa, M., Kato, Y., Yamadera, T., Bae, E.-K., Toriyama, S., Ikeda, R., Zhang, L., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601490 · Cited by 275 · see citing works

Stage-specific sensitivity to p53 restoration during lung cancer progression

Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Rivera, F. J. S., Resnick, R., Bronson, R. T., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 271 · see citing works

Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53

Garcı́a-Echeverrı́a, C., Chêne, P., Blommers, M. J. J., & Furet, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990966p · Cited by 246 · see citing works

Selective activation of p53-mediated tumour suppression in high-grade tumours

Junttila, M. R., Karnezis, A. N., Garcia, D. A., Madriles, F., Kortlever, R. M., Rostker, F., Swigart, L. B., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 244 · see citing works

The Roles of SIRT1 in Cancer

Lin, Z., & Fang, D. (2013) · Genes & Cancer · doi:10.1177/1947601912475079 · Cited by 241 · see citing works

The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent

Whitesell, L. J., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., & Cook, P. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1517 · Cited by 206 · see citing works

Targeting the p53–MDM2 interaction to treat cancer

Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204 · see citing works

Chaperone-mediated autophagy degrades mutant p53Preprint

Vakifahmetoglu-Norberg, H., Kim, M., Xia, H., Iwanicki, M., Ofengeim, D., Coloff, J. L., Pan, L., Ince, T. A., Kroemer, G., Brugge, J. S., et al. (2013) · Genes & Development · doi:10.1101/gad.220897.113 · Cited by 204 · see citing works

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · see citing works

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190 · see citing works

Dual-Site Regulation of MDM2 E3-Ubiquitin Ligase Activity

Wallace, M., Worrall, E. G., Pettersson, S., Hupp, T. R., & Ball, K. L. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.029 · Cited by 171 · see citing works

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

Rew, Y., Sun, D., de Turiso, F. G.-L., Bartberger, M. D., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Deignan, J., Fox, B. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300354j · Cited by 166 · see citing works

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 164 · see citing works

Current strategies to target p53 in cancer

Chen, F., Wang, W., & El‐Deiry, W. S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.031 · Cited by 158 · see citing works

Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein−Protein Interaction: Structure−Activity Studies Leading to Improved Potency

Hardcastle, I. R., Liu, J., Valeur, E., Watson, A. F., Ahmed, S. U., Blackburn, T. J., Bennaceur, K., Clegg, W., Drummond, C. J., Endicott, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1011929 · Cited by 152 · see citing works

The C terminus of p53 binds the N-terminal domain of MDM2

Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I. L., Gabizon, R., Mattia, M., Zupnick, A., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1872 · Cited by 148 · see citing works

Structural evolution of p53, p63, and p73: Implication for heterotetramer formation

Joerger, A. C., Rajagopalan, S., Natan, E., Veprintsev, D. B., Robinson, C. V., & Fersht, A. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905867106 · Cited by 142 · see citing works

The ubiquitination code: a signalling problem

Woelk, T., Sigismund, S., Penengo, L., & Polo, S. (2007) · Cell Division · doi:10.1186/1747-1028-2-11 · Cited by 140 · see citing works

The central region of HDM2 provides a second binding site for p53

Yu, G. W., Rüdiger, S., Veprintsev, D. B., Freund, S. M. V., Fernández-Fernández, M. R., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510343103 · Cited by 139 · see citing works

MicroRNA Control of p53

Liu, J., Zhang, C., Zhao, Y., & Feng, Z. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25609 · Cited by 139 · see citing works

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131 · see citing works

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

de Jonge, M. J. A., de Weger, V. A., Dickson, M. A., Langenberg, M. H. G., Cesne, A. L., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.005 · Cited by 130 · see citing works

Small Molecule Inhibitors of the MDM2-p53 Interaction Discovered by Ensemble-Based Receptor Models

Bowman, A. L., Nikolovska‐Coleska, Z., Zhong, H. A., Wang, S., & Carlson, H. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073687x · Cited by 127 · see citing works

Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo

Whitesell, L. J., Sutphin, P. D., An, W. G., Schulte, T. W., Blagosklonny, M. V., & Neckers, L. (1997) · Oncogene · doi:10.1038/sj.onc.1201120 · Cited by 127 · see citing works

Discovery of Novel Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction

Gollner, A., Rudolph, D., Arnhof, H., Bauer, M., Blake, S. M., Boehmelt, G., Cockroft, X.-L., Dahmann, G., Ettmayer, P., Gerstberger, T., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00900 · Cited by 123 · see citing works

Molecular basis of Pirh2-mediated p53 ubiquitylation

Sheng, Y., Laister, R. C., Lemak, A. S., Wu, B., Tai, E., Duan, S., Lukin, J. A., Sunnerhagen, M., Srisailam, S., Karra, M., et al. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1521 · Cited by 116 · see citing works

The Conformationally Flexible S9–S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo

Shimizu, H., Burch, L. R., Smith, A. J., Dornan, D., Wallace, M., Ball, K. L., & Hupp, T. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202296200 · Cited by 116 · see citing works

MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy

Orellana, E. A., & Kasinski, A. L. (2015) · Cancers · doi:10.3390/cancers7030842 · Cited by 115 · see citing works

Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction

Riedinger, C., Endicott, J., Kemp, S. J., Smyth, L. A., Watson, A. F., Valeur, E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Noble, M. E. M., et al. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8062088 · Cited by 113 · see citing works

Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis

Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W. (2013) · Nature Communications · doi:10.1038/ncomms3996 · Cited by 108 · see citing works

p53 protein variants: structural and functional similarities with p63 and p73 isoforms

Courtois-Cox, S., de Fromentel, C. C., & Hainaut, P. L. (2004) · Oncogene · doi:10.1038/sj.onc.1206929 · Cited by 102 · see citing works

TRIM24 Is a p53-Induced E3-Ubiquitin Ligase That Undergoes ATM-Mediated Phosphorylation and Autodegradation during DNA Damage

Jain, A. K., Allton, K. L., Duncan, A. D., & Barton, M. C. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01705-12 · Cited by 99 · see citing works

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

Zhang, Z., Chu, X., Liu, J., Ding, Q., Zhang, J., Bartkovitz, D., Jiang, N., Karnachi, P., So, S., Tovar, C., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400359z · Cited by 90 · see citing works

CARPs Are Ubiquitin Ligases That Promote MDM2-independent p53 and Phospho-p53ser20 Degradation

Yang, W., Rozan, L. M., McDonald, E. R., Navaraj, A., Liu, J. J., Matthew, E. M., Wang, W., Dicker, D. T., & El‐Deiry, W. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m610793200 · Cited by 88 · see citing works

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

Long, J., Parkin, B. L., Ouillette, P. D., Bixby, D. L., Shedden, K., Erba, H. P., Wang, S., & Malek, S. N. (2010) · Blood · doi:10.1182/blood-2010-01-261628 · Cited by 85 · see citing works

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

Arnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23409 · Cited by 85 · see citing works

Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction

González, A. Z., Eksterowicz, J. E., Bartberger, M. D., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Duquette, J., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401767k · Cited by 84 · see citing works

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Furet, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., Holzer, P., Mah, R., Stutz, S., Vaupel, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.010 · Cited by 80 · see citing works

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction

Furet, P., Chêne, P., Pover, A. D., Stachyra, T., Lisztwan, J. H., Kallen, J. A., & Masuya, K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.083 · Cited by 73 · see citing works

Regulation of the Mdm2–p53 pathway by the ubiquitin E3 ligase MARCH7

Zhao, K., Yang, Y., Zhang, G., Wang, C., Wang, D., Wu, M., & Mei, Y. (2018) · EMBO Reports · doi:10.15252/embr.201744465 · Cited by 72 · see citing works

Gambogic acid‐induced degradation of mutant p53 is mediated by proteasome and related to CHIP

Wang, J., Zhao, Q. J., Qi, Q., Gu, H.-Y., Rong, J., Mu, R., Zou, M., Tao, L., You, Q., & Guo, Q. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22941 · Cited by 67 · see citing works

The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Shen, J., Li, P., Shao, X., Yang, Y., Liu, X., Feng, M., Yu, Q., Hu, R., & Wang, Z. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1805 · Cited by 66 · see citing works

Structure and recognition of polyubiquitin chains of different lengths and linkage

Fushman, D., & Wilkinson, K. D. (2011) · F1000 Biology Reports · doi:10.3410/b3-26 · Cited by 65 · see citing works

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

Higgins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0460 · Cited by 63 · see citing works

Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53

Wang, L., He, G., Zhang, P., Wang, X., Jiang, M. H., & Yu, L. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0099-x · Cited by 60 · see citing works

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

Zhang, Z., Ding, Q., Liu, J.-J., Zhang, J., Jiang, N., Chu, X.-J., Bartkovitz, D., Luk, K.-C., Janson, C., Tovar, C., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.072 · Cited by 60 · see citing works

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53–MDM2 interaction with a distinct binding mode

Gessier, F., Kallen, J. A., Jacoby, E., Chêne, P., Stachyra, T., Ruetz, S., Jeay, S., Holzer, P., Masuya, K., & Furet, P. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.058 · Cited by 59 · see citing works

topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage

Lin, L., Ozaki, T., Takada, Y., Kageyama, H., Nakamura, Y., Hata, A., Zhang, J., Simonds, W. F., Nakagawara, A., & Koseki, H. (2005) · Oncogene · doi:10.1038/sj.onc.1208554 · Cited by 57 · see citing works

Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets

Ma, B., Pan, Y., Zheng, J., Levine, A. J., & Nussinov, R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm192 · Cited by 56 · see citing works

Pirh2 RING‐finger E3 ubiquitin ligase: Its role in tumorigenesis and cancer therapy

Jung, Y.-S., Qian, Y., & Chen, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.052 · Cited by 54 · see citing works

When the guardian sleeps: Reactivation of the p53 pathway in cancer

Merkel, O., Taylor, N., Prutsch, N., Staber, P. B., Moriggl, R., Turner, S. D., & Kenner, L. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.02.003 · Cited by 54 · see citing works

Therapeutic prospects for p73 and p63: Rising from the shadow of p53

Vilgelm, A. E., El-Rifai, W. M., & Zaika, A. I. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.001 · Cited by 53 · see citing works

Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein

Yoon, S. Y., Lee, Y., Kim, J. H., Chung, A., Joo, J. H., Kim, C.-N., Kim, N.-S., Choe, I. S., & Kim, J. W. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.004 · Cited by 45 · see citing works

Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction

Rew, Y., Sun, D., Yan, X., Beck, H. P., Canon, J. R., Chen, A., Duquette, J., Eksterowicz, J. E., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501550p · Cited by 45 · see citing works

The p73 Tumor Suppressor Is Targeted by Pirh2 RING Finger E3 Ubiquitin Ligase for the Proteasome-dependent Degradation

Jung, Y.-S., Qian, Y., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.261537 · Cited by 42 · see citing works

Reviewing the future of the P53 field

Levine, A. J. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.181 · Cited by 38 · see citing works

Tetra-substituted imidazoles as a new class of inhibitors of the p53–MDM2 interaction

Vaupel, A., Bold, G., Pover, A. D., Stachyra, T., Lisztwan, J. H., Kallen, J. A., Masuya, K., & Furet, P. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.039 · Cited by 37 · see citing works

Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold

Miyazaki, M., Naito, H., Sugimoto, Y., Kawato, H. C., Okayama, T., Shimizu, H., Miyazaki, M., Kitagawa, M., Seki, T., Fukutake, S., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.091 · Cited by 36 · see citing works

A Novel Naphthalimide Compound Restores p53 Function in Non-small Cell Lung Cancer by Reorganizing the Bak·Bcl-xl Complex and Triggering Transcriptional Regulation

Zhang, G., An, Y.-F., Lü, X., Zhong, H., Zhu, Y., Wu, Y., Ma, F.-E., Yang, J., Liu, Y., Zhou, Z., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.669978 · Cited by 36 · see citing works

A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction

Surmiak, E., Twarda‐Clapa, A., Żak, K. M., Musielak, B., Tomala, M. D., Kubica, K., Grudnik, P., Madej, M., Jabłoński, M., Potempa, J., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00596 · Cited by 36 · see citing works

Negative auto-regulators trap p53 in their web

Zhou, X. Y., Cao, B., & Lu, H. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx001 · Cited by 36 · see citing works

The microRNA feedback regulation of p63 in cancer progression

Lin, C., Li, X., Zhang, Y., Guo, Y., Zhou, J., Gao, K., Dai, J., Hu, G. M., Lv, L., Du, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3020 · Cited by 31 · see citing works

1,4,5-Trisubstituted Imidazole-Based p53–MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers

Twarda‐Clapa, A., Krzanik, S., Kubica, K., Guzik, K., Łabuzek, B., Neochoritis, C. G., Khoury, K., Kowalska, K., Czub, M., Dubin, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00104 · Cited by 31 · see citing works

COP1D, an alternatively spliced constitutive photomorphogenic-1 (COP1) product, stabilizes UV stress-induced c-Jun through inhibition of full-length COP1

Savio, M. G., Rotondo, G., Maglie, S., Rossetti, G., Bender, J. R., & Pardi, R. (2007) · Oncogene · doi:10.1038/sj.onc.1210892 · Cited by 27 · see citing works

Design, Synthesis and Biological Evaluation of Sulfamide and Triazole Benzodiazepines as Novel p53-MDM2 Inhibitors

Yu, Z., Zhuang, C., Wu, Y., Guo, Z., Li, J., Dong, G., Yao, J., Sheng, C., Miao, Z., & Zhang, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150915741 · Cited by 25 · see citing works

Discovery of novel dihydroimidazothiazole derivatives as p53–MDM2 protein–protein interaction inhibitors: Synthesis, biological evaluation and structure–activity relationships

Miyazaki, M., Kawato, H. C., Naito, H., Ikeda, M., Miyazaki, M., Kitagawa, M., Seki, T., Fukutake, S., Aonuma, M., & Soga, T. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.086 · Cited by 20 · see citing works

Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness

Galtsidis, S., Logotheti, S., Pavlopoulou, A., Zampetidis, C., Papachristopoulou, G., Scorilas, A., Vojtesek, B., Gorgoulis, V. G., & Zoumpourlis, V. C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.036 · Cited by 18 · see citing works

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin

Laroche, A., Tran-Cong, K., Chaire, V., Lagarde, P., Hostein, I., Coindre, J., Chibon, F., Neuville, A., Lesluyes, T., Lucchesi, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137794 · Cited by 10 · see citing works

Rational design of promiscuous binding modulators of p53 inducing E3(Ub)-ligases (Mdm2 and Pirh2) as anticancer agents: an in silico approach

Niazi, S., & Purohit, M. N. (2015) · MedChemComm · doi:10.1039/c5md00319a · Cited by 5 · see citing works

Tumor suppressor p63 regulates Pirh2 ubiquitin ligase expression

Daks, A. A., Petukhov, A., Shuvalov, O. Y., Vasileva, E., Melino, G., Barlev, N. A., & Fedorova, O. (2016) · Cell and Tissue Biology · doi:10.1134/s1990519x16030044 · Cited by 4 · see citing works

Identification of Pirh2E and Pirh2F, two additional novel isoforms of Pirh2 ubiquitin ligase from human hepatocellular liver carcinoma cell line

Dong, L., Liu, Y., Qiu, Y., Peng, B., Yin, J., Liu, W., & He, X. (2012) · Bio-Medical Materials and Engineering · doi:10.3233/bme-2012-0693 · Cited by 3 · see citing works

Proteasome Inhibitor Drugs

Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309 · see citing works

Anti-cancer effects of polyphenols via targeting p53 signaling pathway: updates and future directions

Khan, H. Z., Reale, M., Ullah, H., Sureda, A., Tejada, S., Wang, Y., Zhang, Z., & Xiao, J. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.007 · Cited by 157 · see citing works

miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools

Galvão-Lima, L. J., de Morais, A. H. F., Valentim, R. A. D. M., & Barreto, É. J. S. D. S. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00857-9 · Cited by 161 · see citing works

Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace

Singh, N., Chaput, L., & Villoutreix, B. O. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa034 · Cited by 123 · see citing works

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

Tundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 115 · see citing works

Advances in targeted degradation of endogenous proteins

Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92 · see citing works

The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy

Nininahazwe, L., Liu, B., He, C., Zhang, H., & Chen, Z. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.028 · Cited by 92 · see citing works

Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway

Shen, Q., Deng, H., Wang, S.-B., Tian, Y.-S., & Quan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.005 · Cited by 69 · see citing works

Role of Dietary Antioxidants in p53‐Mediated Cancer Chemoprevention and Tumor Suppression

Merlin, J. P. J., Rupasinghe, H. P. V., Dellaire, G., & Murphy, K. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9924328 · Cited by 68 · see citing works

Cotranslational Mechanisms of Protein Biogenesis and Complex Assembly in Eukaryotes

Morales-Polanco, F., Lee, J. H., Barbosa, N. M., & Frydman, J. (2022) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-121721-095858 · Cited by 58 · see citing works

p28 Bacterial Peptide, as an Anticancer Agent

Yaghoubi, A., Khazaei, M., Avan, A., Hasanian, S. M., Cho, W. C. S., & Soleimanpour, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01303 · Cited by 56 · see citing works

Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy

Harakandi, C., Nininahazwe, L., Xu, H., Liu, B., He, C., Zheng, Y., & Zhang, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105273 · Cited by 52 · see citing works

The activated ATM/p53 pathway promotes autophagy in response to oxidative stress-mediated DNA damage induced by Microcystin-LR in male germ cells

Tian, Z., Liu, H., Chen, X., Losiewicz, M. D., Wang, R., Du, X., Wang, B., Ya, M., Zhang, S., Shi, L., et al. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112919 · Cited by 43 · see citing works

Anticancer Actions of Azurin and Its Derived Peptide p28

Huang, F., Shu, Q., Qin, Z., Tian, J., Su, Z., Huang, Y., & Gao, M. (2020) · The Protein Journal · doi:10.1007/s10930-020-09891-3 · Cited by 41 · see citing works

Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells

Pu, Q., Lv, Y., Dong, K., Geng, W., & Gao, H. (2020) · BMC Cancer · doi:10.1186/s12885-020-07069-9 · Cited by 40 · see citing works

Ring finger protein 19A is overexpressed in non‐small cell lung cancer and mediates p53 ubiquitin‐degradation to promote cancer growth

Cheng, Y., Hu, Y., Wang, H., Zhao, Z. Q., Jiang, X., Zhang, Y., Zhang, J., Tong, Y. A., & Qiu, X. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16674 · Cited by 29 · see citing works

Synthesis of new N , N ′-Pd(Pt) complexes based on sulfanyl pyrazoles, and investigation of their in vitro anticancer activity

Akhmetova, V. R., Akhmadiev, N. S., Abdullin, M. F., Dzhemileva, L. U., & D'yakonov, V. A. (2020) · RSC Advances · doi:10.1039/c9ra09783j · Cited by 28 · see citing works

Valorization of Onion Waste by Obtaining Extracts Rich in Phenolic Compounds and Feasibility of Its Therapeutic Use on Colon Cancer

Paesa, M., Nogueira, D. P., Rodríguez, G. R. V., Esparza, I., Jiménez‐Moreno, N., Mendoza, G., Osada, J., Martín‐Belloso, O., Rodriguez‐Yoldi, M. J., & Ancín‐Azpilicueta, C. (2022) · Antioxidants · doi:10.3390/antiox11040733 · Cited by 29 · see citing works

Current landscape of the immunoproteasome: implications for disease and therapy

Zou, Z., Hao, Y., Tao, Z., Ye, W., Luo, Z., Li, X., Li, R., Zheng, K., Xia, J., Guo, C., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02698-0 · Cited by 27 · see citing works

Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer

Gâtel, P., Piechaczyk, M., & Bossis, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_2 · Cited by 22 · see citing works

Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies

Song, Y., Ren, X., Xiong, J., Wang, W., Zhao, Q., Chang, J., & Yu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00102 · Cited by 22 · see citing works

Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation

Zhang, Y., Cui, N., & Zheng, G. (2020) · Oncology Letters · doi:10.3892/ol.2020.11261 · Cited by 21 · see citing works

Interplay between HMGA and TP53 in cell cycle control along tumor progression

Costa, N. M. D., Palumbo, A., Martino, M. D., Fusco, A., Pinto, L. F. R., & Nasciutti, L. E. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03634-4 · Cited by 20 · see citing works

Ubiquitin–proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Zhao, C., Zeng, C., Wang, K., He, Q., Yang, B., Zhou, F., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0441-3 · Cited by 18 · see citing works

miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop

Chen, Q., Wang, W., Chen, S., Chen, X., & Lin, Y. Q. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00266-9 · Cited by 18 · see citing works

Autophagic feedback-mediated degradation of IKKα requires CHK1- and p300/CBP-dependent acetylation of p53

Xu, X., Zhang, C., Xu, H., Wu, L., Hu, M., & Song, L. (2020) · Journal of Cell Science · doi:10.1242/jcs.246868 · Cited by 17 · see citing works

Pirh2-dependent DNA damage in neurons induced by the G-quadruplex ligand pyridostatin

Escarcega, R. D., Patil, A. A., Moruno-Manchon, J. F., Urayama, A., Marrelli, S. P., Kim, N., Monchaud, D., McCullough, L. D., & Tsvetkov, A. S. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105157 · Cited by 16 · see citing works

mTORC1 accelerates osteosarcoma progression via m6A-dependent stabilization of USP7 mRNA

Yang, Z., Yu, W., Xu, A., Liu, B., Jin, L., Tao, H., & Wang, D. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01893-9 · Cited by 16 · see citing works

Inhibitors of APE1 redox and ATM synergistically sensitize osteosarcoma cells to ionizing radiation by inducing ferroptosis

Xiao, H., Jiang, N., Zhang, H., Wang, S., Pi, Q., Chen, H., He, X., Luo, W. F., Lu, Y., Deng, Y., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112672 · Cited by 16 · see citing works

KRAB domain of ZFP568 disrupts TRIM28-mediated abnormal interactions in cancer cells

Kumar, J., Kaur, G., Ren, R., Lu, Y., Lin, K., Li, J., Huang, Y., Patel, A. B., Barton, M. C., Macfarlan, T. S., et al. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa007 · Cited by 16 · see citing works

The p53 protein is a suppressor of Atox1 copper chaperon in tumor cells under genotoxic effects

Tsymbal, S. A., Refeld, A. G., Zatsepin, V. V., & Kuchur, O. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0295944 · Cited by 14 · see citing works

Potential Alternative Therapeutic Modalities for Management Head and Neck Squamous Cell Carcinoma: A Review

Afshari, K., & Sohal, K. S. (2023) · Cancer Control · doi:10.1177/10732748231185003 · Cited by 13 · see citing works

Metallothionein 1M (MT1M) inhibits lung adenocarcinoma cell viability, migration, and expression of cell mobility-related proteins through MDM2/p53/MT1M signaling

Xu, W., Jiang, G., Shi, G., Chen, M., Ma, T., & Tan, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.02.61 · Cited by 13 · see citing works

Sustained-Release and pH-Adjusted Alginate Microspheres-Encapsulated Doxorubicin Inhibit the Viabilities in Hepatocellular Carcinoma-Derived Cells

Pan, C.-T., Yu, R.-S., Yang, C.-J., Chen, L.-R., Wen, Z., Chen, N.-Y., Ou, H., Yu, C., & Shiue, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091417 · Cited by 12 · see citing works

The roles of ribosomal proteins in nasopharyngeal cancer: culprits, sentinels or both

Sim, E. U., Lee, C. W., & Narayanan, K. (2021) · Biomarker Research · doi:10.1186/s40364-021-00311-x · Cited by 12 · see citing works

TRIM25, TRIM28 and TRIM59 and Their Protein Partners in Cancer Signaling Crosstalk: Potential Novel Therapeutic Targets for Cancer

Chiang, D. C., & Yap, B. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100638 · Cited by 10 · see citing works

PA28γ, an Accomplice to Malignant Cancer

Lei, K., Bai, H., Sun, S., Xin, C., Li, J., & Chen, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584778 · Cited by 10 · see citing works

Inhibition of EED activity enhances cell survival of female germline stem cell and improves the oocytes production during oogenesis in vitro

Wang, J., Fang, J., Feng, M., Li, L., Ma, L., Zhao, X., & Dai, Y. (2023) · Open Biology · doi:10.1098/rsob.220211 · Cited by 10 · see citing works

Development and tumorigenic potential of TP53: A therapeutic target for head and neck squamous cell carcinoma

Jayaraman, S., Yasothkumar, D., Priya, V. V., Raj, A. T., Babu, S. D., & Patil, S. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105922 · Cited by 7 · see citing works

Alternative RNA splicing in cancer: what about adult T-cell leukemia?

Tram, J., Mesnard, J.-M., & Péloponèse, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.959382 · Cited by 6 · see citing works

USP33 Regulates DNA Damage Response and Carcinogenesis Through Deubiquitylating and Stabilising p53

Zhu, Y., Chen, Z., Niu, K., Li, M., Deng, Y., Zhang, J., Wei, D., Wang, J., & Zhao, Y. (2024) · Cell Proliferation · doi:10.1111/cpr.13793 · Cited by 6 · see citing works

Restoration of p53 Functions By Suppression of mortalin–p53 Sequestration: an Emerging Target in Cancer Therapy

Akshatha, H. S., Bhagyalalitha, M., Pujar, G. V., Hariharapura, R. C., Sethu, A. K., Singh, M., & Bidye, D. P. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0061 · Cited by 6 · see citing works

Stereoselective Synthesis of Polysubstituted Dihydropyrroles via 1,5‐Addition and N‐1,4‐Addition Cascade

Zhang, J., Wang, Y., Chen, L., Ma, C., & He, Z. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202401350 · Cited by 5 · see citing works

P53 Gene Expression and Nitric Oxide Levels after Artemisinin-Caffeine Treatment in Breast, Lungs and Liver of DMBA-Induced Tumorigenesis

Dokunmu, T. M., Opara, S. C., Imaga, N. A., Awani, O. U., Enoma, D., & Adelani, B. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.2.451 · Cited by 4 · see citing works

Anticancer activity of Pseudomonas aeruginosa derived peptide with iRGD in colon cancer therapy.

Yaghoubi, A., Movaqar, A., Asgharzadeh, F., Derakhshan, M., Ghazvini, K., Hasanian, S. M., Avan, A., Mostafapour, A., Khazaei, M., & Soleimanpour, S. (2023) · PubMed Central · doi:10.22038/ijbms.2023.68331.14913 · Cited by 4 · see citing works

Paracrine Placental Growth Factor Signaling in Response to Ionizing Radiation Is p53-Dependent and Contributes to Radioresistance

Kazimova, T., Tschanz, F., Sharma, A., Telarović, I., Wachtel, M., Pedot, G., Schäfer, B. W., & Pruschy, M. N. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0403 · Cited by 4 · see citing works

Targeting oncogenic signaling pathways in lung Cancer: The emerging role of nobiletin, a flavonoid from citrus peel

Suwal, N., Thapa, R., Bashyal, S., Sugandhi, V. V., Subedi, S., Panth, N., Amorim, N. M. L., Choi, J. P., Gupta, M., Idrees, S., et al. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106887 · Cited by 2 · see citing works

Stereodivergent Synthesis of Chiral Hydrobenzofuranpyrrolidines by Catalytic Asymmetric Dearomative Cyclization and Controlled Epimerization

Liu, W., Huang, Y., Dai, Z., Yu, M., Liu, X., Yao, W., & Han, X. (2024) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202401194 · Cited by 2 · see citing works

Genome-wide screening in human embryonic stem cells identifies genes and pathways involved in the p53 pathway

Haddad, A., Golan‐Lev, T., Benvenisty, N., & Goldberg, M. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01141-5 · Cited by 2 · see citing works

COP1 drives renal cell carcinoma progression by targeting ACSL4 for ubiquitin-mediated degradation and inhibiting ferroptosis

Zheng, Y., Jiang, L., Qi, F., & Peng, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570727 · Cited by 2 · see citing works

Tumor Biology and Metastasis

Argyle, D. J., Khanna, C., & Giancristofaro, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-59496-7.00002-5 · Cited by 2 · see citing works

Human papillomavirus-mediated carcinogenesis and tumor progression

Abboodi, F. F., Delva, N. C., Emmel, J., Renrick, A. N., Buckhaults, P., Banister, C. E., Creek, K. E., & Pirisi, L. A. (2021) · Genome Instability & Disease · doi:10.1007/s42764-021-00038-x · Cited by 1 · see citing works

Genes in Tumor Formation

Riede, I. (2019) · Journal of Hematology and Oncology Research · doi:10.14302/issn.2372-6601.jhor-19-2986 · Cited by 1 · see citing works

Analysis of P53 Gene Mrna Expression and Caspase-3 Levels As Pre-Cervical Cancer Animals Model in Wistar Rat With Diethylstilbestrol-Induced

Rahayu, S. R., Natzird, R., Massie, M. N., Rauf, S., Sujuti, D., Hatta, M., Taslim, N. A. A., Cangara, M. H., Patellongi, I., & Djawad, K. (2019) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1363/1/012093

Association of p53 (P72R) gene polymorphism with increased risk of diabetes mellitus in center of Iran (Tehran)

Mokhtariye, A., Dadashi, A., Vahidi, M., Malekabad, E. S., Naei, V. Y., & Khorramnia, S. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101164

Ciências Biológicas: Campo Promissor em Pesquisa 4

Lemos, J. R. (2020) · doi:10.22533/at.ed.404202406

p53

Chiaravalli, A. M., & Pascarella, R. D. (2020) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_5093-1

TP53

Chiaravalli, A. M., & Pascarella, R. D. (2020) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_5097-1

p53

Chiaravalli, A. M., & Pascarella, R. D. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-030-62345-6_5093

TP53

Chiaravalli, A. M., & Pascarella, R. D. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-030-62345-6_5097

Data from Paracrine Placental Growth Factor Signaling in Response to Ionizing Radiation Is p53-Dependent and Contributes to Radioresistance

Kazimova, T., Tschanz, F., Sharma, A., Telarović, I., Wachtel, M., Pedot, G., Schäfer, B. W., & Pruschy, M. N. (2023) · doi:10.1158/1541-7786.c.6545129.v1

Synergistic inhibition of APE1 redox activity and ATM activation sensitizes osteosarcoma cells to ionizing radiation by inducing ferroptosisPreprint

Xiao, H.-X., Jiang, N., Zhang, H., Wang, S., Pi, Q., Chen, H., He, X., Luo, W. F., Deng, Y., Lu, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3907908/v1

Caractérisation moléculaire du domaine de liaison à l'ARN de la protéine non-structurale 1 (NS1) des virus influenza A lors de l'interaction avec un ARN double-brin de haute affinité contenant des séquences sélectionnées in vitro

Wacquiez, A. (2020) · theses.fr (ABES) · doi:10.70675/8b88f11ez1daaz4387z9531z0dbc55b3ec14

Rôles et régulation des isoformes protéiques d'HBZ du HTLV-1 & de Fra-2 dans la Leucémie T de l'Adulte

Tram, J. (2022) · theses.fr (ABES) · doi:10.70675/1ae465a5zeef2z4046za34cz561b7f0bf021

BindingDB Entry 50023269: Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies.

BindingDB (2026) · UC San Diego · doi:10.7270/q2891bs1

Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway

Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69 · see citing works

Ubiquitin E3 ligases controlling p53 stability

Lee, S. W., Seong, M. W., Jeon, Y. J., & Chung, C. H. (2012) · Animal Cells and Systems · doi:10.1080/19768354.2012.688769 · Cited by 9 · see citing works

Regulating the p53 system through ubiquitination

Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 179 · see citing works

Essential Roles of E3 Ubiquitin Ligases in p53 Regulation

Sane, S., & Rezvani, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020442 · Cited by 76 · see citing works

It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53

Love, I. M., & Grossman, S. R. (2012) · Genes & Cancer · doi:10.1177/1947601912455198 · Cited by 28 · see citing works